Market demand for citrate products will grow

Regional citrate anticoagulation (RCA) is a hemodialysis anticoagulation technique. As a metabolic intermediate product, citric acid participates in material metabolism, energy metabolism, etc. in the human body. In local anticoagulation, citric acid can combine with free calcium and magnesium in large amounts to form stable calcium citrate and magnesium citrate. Reduces ionized calcium levels in the extracorporeal circuit, thereby blocking the intrinsic and extrinsic coagulation pathways. Local citrate anticoagulation is currently the most economical, safe, and effective anticoagulation method, and it is also the preferred anticoagulation method for continuous renal replacement therapy (CRRT).

According to the "2023-2027 China Local Citrate Anticoagulation (RCA) Market Monitoring and Future Development Prospects Research Report" released by the New Sijie Industry Research Center, there are currently 4 citrate products used as CRRT local anticoagulation. There are two types: % trisodium citrate solution and citric acid-citrate-dextrose blood preservation solution (ACD solution), of which 4% trisodium citrate solution is the most commonly used. Relevant suppliers of citric acid products include Chengdu Qingshan Likang Pharmaceutical, Sichuan Nangel Biotechnology, Hunan Huari Pharmaceutical, Shaanxi Hantang Pharmaceutical, Sichuan Mianzhu Hongji Pharmaceutical, etc.

Anticoagulation is the key to preventing coagulation in the extracorporeal circulation circuit during CRRT. With the iteration of technology, anticoagulation methods tend to be diversified. The main anticoagulation methods in CRRT are heparin anticoagulation (UFH), local citrate anticoagulation (RCA), low molecular weight heparin (LMWH) anticoagulation, etc. Compared with heparin anticoagulation, local citrate anticoagulation has the advantages of safety, effectiveness, stable and long-lasting anticoagulation effect, and fewer bleeding complications.

The "Standard Operating Procedures for Blood Purification (2021 Edition)" mentioned that for patients without thromboembolic diseases and their risks, local citrate anticoagulation is recommended as the preferred option for CRRT. CRRT is a commonly used clinical blood purification technology and plays an important role in the treatment of severe acute kidney injury, new coronavirus pneumonia, sepsis, acute necrotizing encephalopathy in children and other diseases. Against the backdrop of an aging population, the increased clinical application demand for CRRT will bring broad space to the local citrate anticoagulation market.

Topical citrate anticoagulation has outstanding advantages and is becoming a new choice for more and more emergency physicians. However, due to incomplete management guidelines, improper clinical treatment, and lack of dedicated calcium-free dialysate and citrate solutions, the clinical use of topical citrate anticoagulation has been limited. Promotion is slow. In order to provide the latest clinical practice guidance, the Emergency Physicians Branch of the Chinese Medical Doctor Association (CMDA) released the "Emergency Expert Consensus on the Management of Citrate Local Anticoagulation in CRRT (2023 Edition)".

Industry analysts in New Thinking said that topical citrate anticoagulation has the advantages of safety, effectiveness, economy, stable and long-lasting effects, etc., and is the preferred anticoagulation method for CRRT. In the context of the aging population, the clinical application of CRRT is expanding, and topical citrate anticoagulation is Anticoagulation market demand will be further released.The application prospect of topical citrate anticoagulation is good, but there are still problems such as lack of dedicated replacement fluid and improper clinical treatment. In the future, topical citrate anticoagulation solutions still need to be transformed into integrated, convenient and safe directions.